Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

1-alpha-hydroxycholecalciferol for renal osteodystrophy

A M Brownjohn, F J Goodwin, W Hately

    British Medical Journal
    |September 17, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Denosumab for the treatment of primary pediatric osteoporosis.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
    Same author

    Treatments of osteoporosis increase bone material strength index in patients with low bone mass.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
    Same author

    Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
    Same author

    Novel Haematological Parameters in Patients Receiving Recombinant Human Erythropoietin and Undergoing Haemodialysis.

    Hematology (Amsterdam, Netherlands)·2016
    Same author

    Serum Dickkopf 1 levels in sclerostin deficiency.

    The Journal of clinical endocrinology and metabolism·2013
    Same author

    D-Amino acids in chronic renal failure and the effects of dialysis and urinary losses.

    Amino acids·2013

    1-alpha-hydroxycholecalciferol (1-alpha-OHD3) effectively treated renal osteodystrophy by improving bone health markers and reducing parathyroid hormone levels. Careful monitoring of calcium is essential due to potential hypercalcemia.

    Area of Science:

    • Nephrology
    • Endocrinology
    • Bone Metabolism

    Background:

    • Renal osteodystrophy is a common complication in patients with chronic kidney disease.
    • Abnormalities in calcium, phosphorus, and vitamin D metabolism contribute to bone disease progression.

    Purpose of the Study:

    • To evaluate the efficacy and safety of 1-alpha-hydroxycholecalciferol (1-alpha-OHD3) in treating renal osteodystrophy.
    • To assess the impact of 1-alpha-OHD3 on biochemical markers and radiological findings.

    Main Methods:

    • A cohort of fourteen patients with renal osteodystrophy received 1-alpha-OHD3 for at least one year.
    • Dosing varied from 1 microgram/week to 3 microgram/day.
    • Plasma calcium, inorganic phosphorus, alkaline phosphatase, and parathyroid hormone levels were monitored.

    Related Experiment Videos

    Main Results:

    • Significant increases in plasma calcium and inorganic phosphorus were observed.
    • Plasma alkaline phosphatase decreased in most patients, normalizing in seven.
    • Serum parathyroid hormone levels decreased significantly, normalizing in eight patients within one year.
    • Radiological abnormalities showed improvement in ten patients.
    • Hypercalcemia occurred in eleven patients, requiring dose adjustments.

    Conclusions:

    • 1-alpha-OHD3 is effective in ameliorating biochemical and radiological abnormalities associated with renal osteodystrophy.
    • Treatment requires careful monitoring of plasma calcium levels to manage potential hypercalcemia.